According to a systematic review and meta-analysis published in the Journal of Investigative Medicine , bisphosphonates, especially zoledronic acid, alendronate and risedronate, can significantly decrease the incidence of hip fracture (IHF) in the general population.

After a database search, 17 publications reporting the results of randomised, double-blind, placebo-controlled clinical trials...